To Get Full Access :

Anzupgo

Anzupgo cream is the first and only topical pan-JAK inhibitor approved for adults with moderate to severe chronic hand eczema. By targeting the JAK-STAT pathway, it provides effective, steroid-free relief from inflammation, itching, and skin damage, giving patients a safer and more convenient alternative to traditional treatments.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Delgocitinib
  • Innovator :

    LEO PHARMA AS
  • Approval Date :

    23-Jul-25
  • NCE-1 Date :

    23-Jul-29
  • NCE Date :

    23-Jul-30
  • Dosage Form :

    Topical Cream
  • Strength :

    20MG
  • Therapeutic Category :

    Dermatologic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    85
  • 2026 :

    94
  • 2027 :

    112
  • 2028 :

    137
  • 2029 :

    169
  • 2030 :

    204
  • 2031 :

    234
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?